Anna Babinska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Babinska has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Yigal H. Ehrlich
Department of Biology, College of Staten Island of The City University of New York 10314, USA
3 shared publications E Kornecki
2 shared publicationsE. Kornecki
Division of Nephrology, Department of Medicine State University of New York, Downstate Medical Center Brooklyn NY 11203
2 shared publications- T. Sobocki
Program in Neuroscience and Department of Chemistry, College of Staten Island, CUNY, 2800 Victory Blvd., 6S-326, Staten Island, NY 10314, USA
2 shared publications A J Norin
1 shared publicationA. Shon
Division of Nephrology, Department of Medicine State University of New York, Downstate Medical Center Brooklyn NY 11203
1 shared publication
Latest Publications
- 7 May 2014
- Published by Wiley in Peptide Science
- Vol. 102 (4) , 322-334
Development of new antiatherosclerotic and antithrombotic drugs utilizing F11 receptor (F11R/JAM‐A) peptides
Peptides with enhanced resistance to proteolysis, based on the amino acid sequence of the F11 receptor molecule (F11R, aka JAM‐A/Junctional adhesion molecule‐A), were designed, prepared, and examined as potential candidates for the development of anti‐atherosclerotic and anti‐thrombotic therapeutic drugs. A sequence at the N‐terminal of F11R together with another sequence located in the first Ig‐loop of this protein, were identified to form a steric active‐site operating in the F11R‐dependent adhesion between cells that express F11R molecules on their external surface. In silico modeling of the complex between two polypeptide chains with the sequences positioned in the active‐site was used to generate peptide‐candidates designed to inhibit homophilic interactions between surface‐located F11R molecules. The two lead F11R peptides were modified with D‐Arg and D‐Lys at selective sites, for attaining higher stability to proteolysis in vivo. Using molecular docking experiments we tested different conformational states and the putative binding affinity between two selected D‐Arg and D‐Lys‐modified F11R peptides and the proposed binding pocket. The inhibitory effects of the F11R peptide 2HN‐(dK)‐SVT‐(dR)‐EDTGTYTC‐CONH2 on antibody‐induced platelet aggregation and on the adhesion of platelets to cytokine‐inflammed endothelial cells are reported in detail, and the results point out the significant potential utilization of F11R peptides for the prevention and treatment of atherosclerotic plaques and associated thrombotic events. © 2014 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 102: 322–334, 2014.
- 7 May 2014
- Published by Wiley in Peptide Science
- Vol. 102 (4) , 322-334
Development of new antiatherosclerotic and antithrombotic drugs utilizing F11 receptor (F11R/JAM‐A) peptides
Peptides with enhanced resistance to proteolysis, based on the amino acid sequence of the F11 receptor molecule (F11R, aka JAM‐A/Junctional adhesion molecule‐A), were designed, prepared, and examined as potential candidates for the development of anti‐atherosclerotic and anti‐thrombotic therapeutic drugs. A sequence at the N‐terminal of F11R together with another sequence located in the first Ig‐loop of this protein, were identified to form a steric active‐site operating in the F11R‐dependent adhesion between cells that express F11R molecules on their external surface. In silico modeling of the complex between two polypeptide chains with the sequences positioned in the active‐site was used to generate peptide‐candidates designed to inhibit homophilic interactions between surface‐located F11R molecules. The two lead F11R peptides were modified with D‐Arg and D‐Lys at selective sites, for attaining higher stability to proteolysis in vivo. Using molecular docking experiments we tested different conformational states and the putative binding affinity between two selected D‐Arg and D‐Lys‐modified F11R peptides and the proposed binding pocket. The inhibitory effects of the F11R peptide 2HN‐(dK)‐SVT‐(dR)‐EDTGTYTC‐CONH2 on antibody‐induced platelet aggregation and on the adhesion of platelets to cytokine‐inflammed endothelial cells are reported in detail, and the results point out the significant potential utilization of F11R peptides for the prevention and treatment of atherosclerotic plaques and associated thrombotic events. © 2014 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 102: 322–334, 2014.
- Open Access
- 26 June 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 98
Transcription and translation of human F11R gene are required for an initial step of atherogenesis induced by inflammatory cytokines
Background -: The F11 Receptor (F11R; aka JAM-A, JAM-1) is a cell adhesion protein present constitutively on the membrane surface of circulating platelets and within tight junctions of endothelial cells (ECs). Previous reports demonstrated that exposure of ECs to pro-inflammatory cytokines causes insertion of F11R molecules into the luminal surface of ECs, ensuing with homologous interactions between F11R molecules of platelets and ECs, and a resultant adhesion of platelets to the inflamed ECs. The main new finding of the present report is that the first step in this chain of events is thede-novotranscription and translation of F11R molecules, induced in ECs by exposure to inflammatory cytokines.Methods -: The experimental approach utilized isolated, washed human platelet suspensions and cultured human venous endothelial cells (HUVEC) and human arterial endothelial cells (HAEC) exposed to the proinflammatory cytokines TNF-alpha and/or IFN-gamma, for examination of the ability of human platelets to adhere to the inflamed ECs thru the F11R. Our strategy was based on testing the effects of the following inhibitors on this activity: general mRNA synthesis inhibitors, inhibitors of the NF-kappaB and JAK/STAT pathways, and small interfering F11R-mRNA (siRNAs) to specifically silence the F11R gene.Results -: Treatment of inflamed ECs with the inhibitors actinomycin, parthenolide or with AG-480 resulted in complete blockade of F11R- mRNA expression, indicating the involvement of NF-kappaB and JAK/STAT pathways in this induction. Transfection of ECs with F11R siRNAs caused complete inhibition of the cytokine-induced upregulation of F11R mRNA and inhibition of detection of the newly- translated F11R molecules in cytokine-inflamed ECs. The functional consequence of the inhibition of F11R transcription and translation was the significant blockade of the adhesion of human platelets to inflamed ECs.Conclusion -: These results prove thatde novosynthesis of F11R in ECs is required for the adhesion of platelets to inflamed ECs. Because platelet adhesion to an inflamed endothelium is crucial for plaque formation in non-denuded blood vessels, we conclude that thede-novotranslation of F11R is a crucial early step in the initiation of atherogenesis, leading to atherosclerosis, heart attacks and stroke.
- 26 June 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 98
Open AccessTranscription and translation of human F11R gene are required for an initial step of atherogenesis induced by inflammatory cytokines
Background -: The F11 Receptor (F11R; aka JAM-A, JAM-1) is a cell adhesion protein present constitutively on the membrane surface of circulating platelets and within tight junctions of endothelial cells (ECs). Previous reports demonstrated that exposure of ECs to pro-inflammatory cytokines causes insertion of F11R molecules into the luminal surface of ECs, ensuing with homologous interactions between F11R molecules of platelets and ECs, and a resultant adhesion of platelets to the inflamed ECs. The main new finding of the present report is that the first step in this chain of events is thede-novotranscription and translation of F11R molecules, induced in ECs by exposure to inflammatory cytokines.Methods -: The experimental approach utilized isolated, washed human platelet suspensions and cultured human venous endothelial cells (HUVEC) and human arterial endothelial cells (HAEC) exposed to the proinflammatory cytokines TNF-alpha and/or IFN-gamma, for examination of the ability of human platelets to adhere to the inflamed ECs thru the F11R. Our strategy was based on testing the effects of the following inhibitors on this activity: general mRNA synthesis inhibitors, inhibitors of the NF-kappaB and JAK/STAT pathways, and small interfering F11R-mRNA (siRNAs) to specifically silence the F11R gene.Results -: Treatment of inflamed ECs with the inhibitors actinomycin, parthenolide or with AG-480 resulted in complete blockade of F11R- mRNA expression, indicating the involvement of NF-kappaB and JAK/STAT pathways in this induction. Transfection of ECs with F11R siRNAs caused complete inhibition of the cytokine-induced upregulation of F11R mRNA and inhibition of detection of the newly- translated F11R molecules in cytokine-inflamed ECs. The functional consequence of the inhibition of F11R transcription and translation was the significant blockade of the adhesion of human platelets to inflamed ECs.Conclusion -: These results prove thatde novosynthesis of F11R in ECs is required for the adhesion of platelets to inflamed ECs. Because platelet adhesion to an inflamed endothelium is crucial for plaque formation in non-denuded blood vessels, we conclude that thede-novotranslation of F11R is a crucial early step in the initiation of atherogenesis, leading to atherosclerosis, heart attacks and stroke.
- 15 April 2000
- Vol. 95 (8) , 2600-9
Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation.
This study demonstrates that the human platelet F11 receptor (F11R) functions as an adhesion molecule, and this finding is confirmed by the structure of the protein as revealed by molecular cloning. The F11R is a 32-/35-kd protein duplex that serves as the binding site through which a stimulatory monoclonal antibody causes platelet aggregation and granule secretion. A physiological role for the F11R protein was demonstrated by its phosphorylation after the stimulation of platelets by thrombin and collagen. A pathophysiological role for the F11R was revealed by demonstrating the presence of F11R-antibodies in patients with thrombocytopenia. Adhesion of platelets through the F11R resulted in events characteristic of the action of cell adhesion molecules (CAMs). To determine the structure of this protein, we cloned the F11R cDNA from human platelets. The predicted amino acid sequence demonstrated that it is an integral membrane protein and an immunoglobulin superfamily member containing 2 extracellular C2-type domains. The structure of the F11R as a member of a CAM family of proteins and its activity in mediating adhesion confirm each another. We conclude that the F11R is a platelet-membrane protein involved in 2 distinct processes initiated on the platelet surface. The first is antibody-induced platelet aggregation and secretion that are dependent on both the FcgammaRII and the GPIIb/IIIa integrin and that may be involved in pathophysiological processes associated with certain thrombocytopenias. The second is an F11R-mediated platelet adhesion that is not dependent on either the FcgammaRII or the fibrinogen receptor and that appears to play a role in physiological processes associated with platelet adhesion and aggregation. (Blood. 2000;95:2600-2609)
- 15 April 2000
- Vol. 95 (8) , 2600-9
Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation.
This study demonstrates that the human platelet F11 receptor (F11R) functions as an adhesion molecule, and this finding is confirmed by the structure of the protein as revealed by molecular cloning. The F11R is a 32-/35-kd protein duplex that serves as the binding site through which a stimulatory monoclonal antibody causes platelet aggregation and granule secretion. A physiological role for the F11R protein was demonstrated by its phosphorylation after the stimulation of platelets by thrombin and collagen. A pathophysiological role for the F11R was revealed by demonstrating the presence of F11R-antibodies in patients with thrombocytopenia. Adhesion of platelets through the F11R resulted in events characteristic of the action of cell adhesion molecules (CAMs). To determine the structure of this protein, we cloned the F11R cDNA from human platelets. The predicted amino acid sequence demonstrated that it is an integral membrane protein and an immunoglobulin superfamily member containing 2 extracellular C2-type domains. The structure of the F11R as a member of a CAM family of proteins and its activity in mediating adhesion confirm each another. We conclude that the F11R is a platelet-membrane protein involved in 2 distinct processes initiated on the platelet surface. The first is antibody-induced platelet aggregation and secretion that are dependent on both the FcgammaRII and the GPIIb/IIIa integrin and that may be involved in pathophysiological processes associated with certain thrombocytopenias. The second is an F11R-mediated platelet adhesion that is not dependent on either the FcgammaRII or the fibrinogen receptor and that appears to play a role in physiological processes associated with platelet adhesion and aggregation. (Blood. 2000;95:2600-2609)
- 1 January 1998
- Vol. 446, 51-71
Surface protein phosphorylation by ecto-protein kinases. Role in neuronal development and synaptic plasticity.
- 1 January 1998
- Vol. 446, 51-71
Surface protein phosphorylation by ecto-protein kinases. Role in neuronal development and synaptic plasticity.
- 1 November 1996
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 271 (5) , H2134-H2144
Activation of human platelets by protein kinase C antibody: role for surface phosphorylation in homeostasis
A monoclonal antibody that inhibits protein kinase C (PKC) activity, as well as PKC pseudosubstrate inhibitory peptides, was found to cause aggregation of human platelets followed by granular secretion. Binding of this antibody to the platelet surface was demonstrated directly by flow cytometry and immunofluorescence microscopy. Assays of ecto-protein kinase activity revealed that this antibody inhibits the phosphorylation of five proteins on the platelet surface. The platelet aggregation induced by extracellular PKC inhibitors could be blocked by the addition of the membrane-impermeable phosphatase inhibitor, microcystin. Thus the inhibition of surface protein phosphorylation together with continuous dephosphorylation, namely, a decrease in the phosphorylation state of surface proteins, causes the activation of platelets. The aggregation caused by decreased surface phosphorylation appears to be initiated by the exposure of active fibrinogen-binding sites on the platelet surface, as demonstrated by the formation of fibrinogen-dependent microaggregates, as the first step in this process. We conclude that the phosphorylation of surface proteins by a platelet ecto-protein kinase C protects platelets from spontaneous aggregation and thus can play an important role in homeostatic mechanisms that maintain circulating platelets in a resting state.
- 1 November 1996
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 271 (5) , H2134-H2144
Activation of human platelets by protein kinase C antibody: role for surface phosphorylation in homeostasis
A monoclonal antibody that inhibits protein kinase C (PKC) activity, as well as PKC pseudosubstrate inhibitory peptides, was found to cause aggregation of human platelets followed by granular secretion. Binding of this antibody to the platelet surface was demonstrated directly by flow cytometry and immunofluorescence microscopy. Assays of ecto-protein kinase activity revealed that this antibody inhibits the phosphorylation of five proteins on the platelet surface. The platelet aggregation induced by extracellular PKC inhibitors could be blocked by the addition of the membrane-impermeable phosphatase inhibitor, microcystin. Thus the inhibition of surface protein phosphorylation together with continuous dephosphorylation, namely, a decrease in the phosphorylation state of surface proteins, causes the activation of platelets. The aggregation caused by decreased surface phosphorylation appears to be initiated by the exposure of active fibrinogen-binding sites on the platelet surface, as demonstrated by the formation of fibrinogen-dependent microaggregates, as the first step in this process. We conclude that the phosphorylation of surface proteins by a platelet ecto-protein kinase C protects platelets from spontaneous aggregation and thus can play an important role in homeostatic mechanisms that maintain circulating platelets in a resting state.